Outcomes of Severe Covid-19 Among Patients Who Did and Did Not Receive Tocilizumab: A Two-year Prospective Cohort Study

Published: Jan. 20, 2025

Evidence about long-term effects of tocilizumab (TCZ) treatment after COVID-19 is sparse. This study explored COVID-19-related outcomes over a two-year period among people who received TCZ and those did not. Patients were recruited from two healthcare centers in Serbia, March 2021 to December 2022. Demographic, clinical, laboratory data collected hospital records. Outcomes years follow-up, such as post-COVID syndrome (PCS) mortality, retrieved records or through telephone calls. Cumulative mortality the cohort (150; 32.8% patients) was 20.6%, non-TCZ (307 patients; 67.2%) 24.7%. In recipients there lower cumulative incidence PCS (3.4% vs. 9.9%, p = 0.018). Predictors both cohorts included age, receiving intensive care unit treatment, having insulin-dependent diabetes, elevated C-reactive protein creatinin kinase on admission. addition, chest pain admission, being smoker, pre-existing respiratory diseases cancer along with high aspartate aminotranspherase admission predictive higher cohort. had rates follow-up. suggests that has potential health benefits for hospitalized COVID-19.

Language: Английский

---

Detection of SARS-CoV-2 in Ascitic Fluid of Cirrhotic COVID-19 Patients: Case Series and Literature Review

COVID, Journal Year: 2025, Volume and Issue: 5(4), P. 58 - 58

Published: April 18, 2025

SARS-CoV-2 has been identified in multiple organs and fluids, including the liver peritoneal fluid. Gastrointestinal symptoms, such as abdominal pain, diarrhea, nausea, vomiting, can exacerbate COVID-19 outcomes by contributing to complications, like acid–base imbalances cardiovascular dysfunction, particularly patients with pre-existing conditions. We report three cases of cirrhotic detected their ascitic fluid review relevant literature on virus’s presence clinical significance These findings underscore diagnostic prognostic challenges managing chronic disease highlight need for further research clarify viral dissemination mechanisms optimize protective measures healthcare workers during surgical procedures.

Language: Английский

---

COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(4), P. 2212 - 2212

Published: Feb. 12, 2024

The pandemic period due to coronavirus disease 2019 (COVID-19) revolutionized all possible areas of global health. Significant consequences were also related diverse extrapulmonary manifestations this pathology. liver was found be a relatively common organ, beyond the respiratory tract, affected by severe acute syndrome coronavirus-2 (SARS-CoV-2). Multiple studies revealed essential role chronic (CLD) in general outcome infection. Present concerns field are direct hepatic caused COVID-19 and pre-existing disorders as risk factors for course Which mechanism has key phenomenon—previously existing disorder or failure SARS-CoV-2—is still not fully clarified. Alcoholic (ALD) constitutes another elucidated context Should toxic effects ethanol already developed cirrhosis its perceived causative triggering factor impairment patients? In face these discrepancies, we decided summarize whole picture infection, paying special attention ALD focusing on pathological pathways COVID-19, toxicity cirrhosis.

Language: Английский

---

Understanding the significance of adipose tissue in the inflammatory response to COVID-19

Obesity Medicine, Journal Year: 2024, Volume and Issue: 47, P. 100538 - 100538

Published: Feb. 28, 2024

Language: Английский

---